{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:17:14Z","timestamp":1792271834768,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s41669-024-00555-x","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:59:40Z","timestamp":1737637180000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pricing for Multi-Indication Drugs in the Italian Regulatory Context"],"prefix":"10.1007","volume":"9","author":[{"given":"Maria Grazia","family":"Ursino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-0551","authenticated-orcid":false,"given":"Annalisa","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Viti","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"555_CR1","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Accessed 7 Jan 2025."},{"key":"555_CR2","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kineret-epar-product-information_en.pdf. Accessed 15 Jan 2025."},{"key":"555_CR3","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf. Accessed 14 Jan 2025."},{"key":"555_CR4","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf. Accessed 15 Oct 2024."},{"key":"555_CR5","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf. Accessed 12 Apr 2024."},{"key":"555_CR6","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_en.pdf. Accessed 20 Sep 2024."},{"key":"555_CR7","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed 16 Jan 2025."},{"key":"555_CR8","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed 13 Jan 2025."},{"key":"555_CR9","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf. Accessed 13 Jan 2025."},{"issue":"2","key":"555_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40258-018-0377-7","volume":"16","author":"U Persson","year":"2018","unstructured":"Persson U, Norlin JM. Multi-indication and combination pricing and reimbursement of pharmaceuticals: opportunities for improved health care through faster uptake of new innovations. Appl Health Econ Health Policy. 2018;16(2):157\u201365. https:\/\/doi.org\/10.1007\/s40258-018-0377-7.","journal-title":"Appl Health Econ Health Policy"},{"issue":"12","key":"555_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40273-018-0716-4","volume":"36","author":"J Mestre-Ferrandiz","year":"2018","unstructured":"Mestre-Ferrandiz J, Zozaya N, Alcal\u00e1 B, Hidalgo-Vega \u00c1. Multi-indication pricing: nice in theory but can it work in practice? Pharmacoeconomics. 2018;36(12):1407\u201320. https:\/\/doi.org\/10.1007\/s40273-018-0716-4.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"555_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40258-019-00517-z","volume":"18","author":"C Campillo-Artero","year":"2020","unstructured":"Campillo-Artero C, Puig-Junoy J, Seg\u00fa-Tolsa JL, Trapero-Bertran M. Price models for multi-indication drugs: a systematic review. Appl Health Econ Health Policy. 2020;18(1):47\u201356. https:\/\/doi.org\/10.1007\/s40258-019-00517-z.","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"555_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40258-022-00737-w","volume":"20","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Mills M, Kanavos P. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Appl Health Econ Health Policy. 2022;20(5):757\u201368. https:\/\/doi.org\/10.1007\/s40258-022-00737-w.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"555_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s41669-023-00406-1","volume":"7","author":"M Mills","year":"2023","unstructured":"Mills M, Kanavos P. Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products: evidence from nine OECD countries. Pharmacoecon Open. 2023;7(4):553\u201365. https:\/\/doi.org\/10.1007\/s41669-023-00406-1.","journal-title":"Pharmacoecon Open."},{"issue":"1","key":"555_CR15","doi-asserted-by":"publisher","first-page":"1964791","DOI":"10.1080\/20016689.2021.1964791","volume":"9","author":"R Lawlor","year":"2021","unstructured":"Lawlor R, Wilsdon T, Darquennes E, Hemelsoet D, Huismans J, Normand R, Roediger A. Accelerating patient access to oncology medicines with multiple indications in Europe. J Mark Access Health Policy. 2021;9(1):1964791. https:\/\/doi.org\/10.1080\/20016689.2021.1964791.","journal-title":"J Mark Access Health Policy."},{"issue":"4","key":"555_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jval.2021.11.1376","volume":"25","author":"V Preckler","year":"2022","unstructured":"Preckler V, Esp\u00edn J. The Role of indication-based pricing in future pricing and reimbursement policies: a systematic review. Value Health. 2022;25(4):666\u201375. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1376.","journal-title":"Value Health."},{"key":"555_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074166","volume":"382","author":"KN Vokinger","year":"2023","unstructured":"Vokinger KN, Glaus CEG, Kesselheim AS, Serra-Burriel M, Ross JS, Hwang TJ. Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011\u201320): retrospective cohort study. BMJ. 2023;382: e074166. https:\/\/doi.org\/10.1136\/bmj-2022-074166.","journal-title":"BMJ"},{"issue":"35","key":"555_CR18","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.22.00535","volume":"40","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial us food and drug administration approval and indication extension of new cancer drugs, 2003\u20132021. J Clin Oncol. 2022;40(35):4095\u2013106. https:\/\/doi.org\/10.1200\/JCO.22.00535.","journal-title":"J Clin Oncol"},{"issue":"11","key":"555_CR19","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jval.2023.06.020","volume":"26","author":"DT Michaeli","year":"2023","unstructured":"Michaeli DT, Michaeli T. Cancer drug prices in the United States: efficacy, innovation, clinical trial evidence, and epidemiology. Value Health. 2023;26(11):1590\u2013600. https:\/\/doi.org\/10.1016\/j.jval.2023.06.020. (Epub 2023 Jul 28 PMID: 37516196).","journal-title":"Value Health."},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12913-023-09095-2","volume":"23","author":"M Mills","year":"2023","unstructured":"Mills M, Michaeli D, Miracolo A, et al. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Serv Res. 2023;23:150. https:\/\/doi.org\/10.1186\/s12913-023-09095-2.","journal-title":"BMC Health Serv Res"},{"key":"555_CR21","unstructured":"https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/iqvia-launch-excellence-for-multi-indication-assets-02-23-forweb.pdf."},{"key":"555_CR22","doi-asserted-by":"crossref","unstructured":"Cole A, Neri M, Cookson G. Expert consensus programme: payment models for multi-indication therapies. OHE consulting report, London: Office of Health Economics. 2021. https:\/\/www.ohe.org\/publications\/payment-models-multi-indication-therapies.","DOI":"10.1016\/j.jval.2021.11.680"},{"issue":"2","key":"555_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s41669-023-00467-2","volume":"8","author":"EE Rossini","year":"2024","unstructured":"Rossini EE, Galeone C, Lucchetti C, Jommi C. From indication-based pricing to blended approach: evidence on the price and reimbursement negotiation in Italy. Pharmacoecon Open. 2024;8(2):251\u201361. https:\/\/doi.org\/10.1007\/s41669-023-00467-2. (Epub 2024 Jan 16. Erratum in: Pharmacoecon Open. 2024 Mar;8(2):345. 10.1007\/s41669-024-00475-w).","journal-title":"Pharmacoecon Open."},{"key":"555_CR24","unstructured":"https:\/\/www.isporitaly.org\/2024\/03\/11\/report-ispor-prezzo-e-rimborso\/."},{"key":"555_CR25","unstructured":"Tavolo di lavoro MaCroSCOPIO: Estensione delle indicazioni dei farmaci e PDTA. https:\/\/macroscopio.it\/tavoli-di-lavoro\/le-estensioni-di-indicazione-dei-farmaci\/."},{"issue":"2","key":"555_CR26","first-page":"163","volume":"4","author":"L Pani","year":"2022","unstructured":"Pani L, Cicchetti A, De Luca A, et al. Pricing for multi-indication medicines: a discussion with Italian experts. Pharmadvance. 2022;4(2):163\u201370.","journal-title":"Pharmadvance."},{"key":"555_CR27","unstructured":"https:\/\/www.aifa.gov.it\/en\/-\/rapporto-sulle-tempistiche-delle-procedure-di-prezzo-e-rimborso-dei-farmaci-nel-quinquennio-2018-2022."},{"key":"555_CR28","unstructured":"https:\/\/www.aifa.gov.it\/en\/farmaci-innovativi."},{"key":"555_CR29","unstructured":"https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html\" \\l \"h.1i2bwkm8zpjo."},{"issue":"1","key":"555_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","volume":"42","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T. Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition. Pharmacoeconomics. 2024;42(1):117\u201331. https:\/\/doi.org\/10.1007\/s40273-023-01320-4.","journal-title":"Pharmacoeconomics"},{"key":"555_CR31","unstructured":"https:\/\/health.ec.europa.eu\/health-technology-assessment\/regulation-health-technology-assessment_en."}],"updated-by":[{"DOI":"10.1007\/s41669-025-00566-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000}}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00555-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00555-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:59:13Z","timestamp":1745855953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00555-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00555-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s41669-025-00566-2","asserted-by":"object"}]},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"29 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised. Due to a typesetting mistake, the conclusion included in the structured abstract was incorrect. The correct conclusion reads as follows: \"The study provides valuable insights into the negotiation outcomes for medicines with multiple therapeutic indications, particularly in onco-hematologic and immunosuppressive areas. The analysis revealed that additional discounts for EoIs averaged 12.5%, with a median of 11%, a value used to assess the impact of specific determinants. A discount higher than 11% was statistically correlated with drugs having more than five indications and oncology treatments, showing their influence in negotiations. However, the savings from discounts were modest relative to the increased drug spending as more indications were approved. This suggests an imbalance between the cost control achieved through discounts and the rising expenditure due to expanded drug use\".","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s41669-025-00566-2","URL":"https:\/\/doi.org\/10.1007\/s41669-025-00566-2","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funds, grants, or other support was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from patients\/participants"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"All authors contributed to the study conception and design, material preparation, and data collection. Statistical analyses were performed by E.A. All the authors have read and approved the final version of the manuscript. All the authors wrote and revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}